Iris Faull

674 total citations
22 papers, 370 citations indexed

About

Iris Faull is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Iris Faull has authored 22 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cancer Research, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Iris Faull's work include Cancer Genomics and Diagnostics (19 papers), Lung Cancer Treatments and Mutations (10 papers) and Genetic factors in colorectal cancer (8 papers). Iris Faull is often cited by papers focused on Cancer Genomics and Diagnostics (19 papers), Lung Cancer Treatments and Mutations (10 papers) and Genetic factors in colorectal cancer (8 papers). Iris Faull collaborates with scholars based in Spain, United States and United Kingdom. Iris Faull's co-authors include Rebecca J. Nagy, Richard B. Lanman, Rafael Rosell, Niki Karachaliou, Emilio Alba, Manuel Ruíz‐Borrego, Federico Rojo, Ignasi Tusquets, Aňa Lluch and José Á. García-Sáenz and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Iris Faull

21 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iris Faull Spain	8	268	198	152	125	97	22	370
Chacha Horombe United States	2	232 0.9×	142 0.7×	107 0.7×	80 0.6×	76 0.8×	3	303
Joseph M. Guenther United States	2	287 1.1×	242 1.2×	96 0.6×	84 0.7×	56 0.6×	2	366
Christine Vietz United States	4	209 0.8×	126 0.6×	131 0.9×	66 0.5×	107 1.1×	12	301
Amy Donahue United States	3	275 1.0×	163 0.8×	172 1.1×	73 0.6×	121 1.2×	5	367
M. Bachner Austria	5	330 1.2×	215 1.1×	111 0.7×	48 0.4×	75 0.8×	7	404
Claudia Lefeuvre France	6	212 0.8×	152 0.8×	134 0.9×	45 0.4×	77 0.8×	15	374
María Luisa Limón Spain	13	207 0.8×	354 1.8×	149 1.0×	170 1.4×	101 1.0×	26	543
C. Alexander United States	4	310 1.2×	193 1.0×	56 0.4×	61 0.5×	142 1.5×	5	403
Rodrigo Gonçalves Brazil	11	190 0.7×	136 0.7×	69 0.5×	74 0.6×	67 0.7×	29	321
Fatemeh Lorenz-Salehi Germany	8	245 0.9×	312 1.6×	170 1.1×	57 0.5×	37 0.4×	17	420

Countries citing papers authored by Iris Faull

Since Specialization

Citations

This map shows the geographic impact of Iris Faull's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Faull with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Faull more than expected).

Fields of papers citing papers by Iris Faull

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Faull. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Faull. The network helps show where Iris Faull may publish in the future.

Co-authorship network of co-authors of Iris Faull

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Faull. A scholar is included among the top collaborators of Iris Faull based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Faull. Iris Faull is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Navani, Neal, Verena Schneider, Riyaz Shah, et al.. (2024). 119 Estimating the health benefits of introducing ctDNA next generation sequencing to the diagnostic pathway for advanced lung cancer: A modelling study. Lung Cancer. 190. 107680–107680. 2 indexed citations

Bessa, Xavier, Joana Vidal, Catalina Márquez-Vega, et al.. (2023). High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer. Annals of Oncology. 34(12). 1187–1193. 29 indexed citations

Benavides, Manuel, Julia Alcaide, Esperanza Torres, et al.. (2022). Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer. ESMO Open. 7(3). 100481–100481. 14 indexed citations

Cui, Wanyuan, Anna Minchom, Jaishree Bhosle, et al.. (2022). Up Front Cell Free DNA Next Generation Sequencing Improves Target Identification in UK First Line Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. SSRN Electronic Journal. 3 indexed citations

Cui, Wanyuan, Anna Minchom, Jaishree Bhosle, et al.. (2022). Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. European Journal of Cancer. 171. 44–54. 18 indexed citations

Mezquita, Laura, Cristina Teixidó, Marta García de Herreros, et al.. (2022). Prevalence of incidental pathogenic germline variants detected in cfDNA in patients with oncogene-driven non-small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). 10569–10569. 6 indexed citations

Vidal, Joana, David Casadevall, Beatríz Bellosillo, et al.. (2021). Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clinical Cancer Research. 27(10). 2890–2898. 62 indexed citations

Alonso, Guzmán, Javier Ros, Helena Verdaguer, et al.. (2021). 6P Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials. Annals of Oncology. 32. S1346–S1348. 1 indexed citations

Durán, M., et al.. (2021). ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report. Journal of Medical Case Reports. 15(1). 89–89. 6 indexed citations

10.

Palmero, Ramón, Álvaro Taus, Santiago Viteri, et al.. (2021). Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer. JCO Precision Oncology. 5(5). 93–102. 38 indexed citations

11.

Martínez‐Sáez, Olga, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2020). 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i). Annals of Oncology. 31. S17–S17.

12.

Cui, Wanyuan, Iris Faull, Rebecca J. Nagy, et al.. (2020). 1352P Circulating tumour (ct) DNA next generation sequencing (NGS) in advanced non-small cell lung cancer (mNSCLC): A UK single institution experience. Annals of Oncology. 31. S867–S867. 1 indexed citations

13.

Benavides, Manuel, Julia Alcaide, Martina Álvarez, et al.. (2020). Clinical utility of comprehensive circulating tumor DNA (ctDNA) testing compared to standard-of-care (SoC) tissue testing in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology. 38(4_suppl). 15–15. 1 indexed citations

14.

Zugazagoitia, Jon, Eloísa Jantus‐Lewintre, Dolores Isla, et al.. (2019). Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer. 134. 72–78. 21 indexed citations

15.

Bracht, Jillian Wilhelmina Paulina, Niki Karachaliou, Richard B. Lanman, et al.. (2019). Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution.. Journal of Clinical Oncology. 37(15_suppl). 9055–9055. 1 indexed citations

16.

Karachaliou, Niki, Martina I. Lefterova, Imane Chaib, et al.. (2018). Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA). Annals of Oncology. 29. viii671–viii671. 1 indexed citations

17.

Palmero, Ramón, Álvaro Taus, Santiago Viteri, et al.. (2018). P2.03-02 Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP). Journal of Thoracic Oncology. 13(10). S716–S717. 2 indexed citations

18.

Rodrigo, Allen G., et al.. (2018). Application of liquid biopsies in metastatic gastrointestinal cancer to identify candidate therapeutic targets. Annals of Oncology. 29. vi1–vi1. 1 indexed citations

19.

Albanell, Joan, Antonio González, Manuel Ruíz‐Borrego, et al.. (2011). Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Annals of Oncology. 23(3). 625–631. 106 indexed citations

20.

Albanell, Joan, Rámón Colomer, Manuel Ruíz‐Borrego, et al.. (2011). P198 Prospective trans-GEICAM study of the impact of the 21-gene recurrence score assay and traditional clinico-pathological factors on clinical decision making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer. The Breast. 20. S43–S43. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact